Archive

Guardant wins FDA nod for diagnostic guiding use of AstraZeneca’s Etcamah

This lets you identify patients eligible for Etcamah using Guardant’s companion test, so treatment selection can be aligned with the approved biomarker strategy.

Medicine · Fierce Biotech · 7 Sept

IIT Madras patents polymer tech that disintegrates bacteria on surfaces without harming human cells

Offers a non-antibiotic surface coating to curb hospital-acquired infections and superbug spread, potentially reducing reliance on conventional antimicrobials.

General Medicine · ETHealthworld · 7 Sept

PIL challenges Centre’s HPV vaccination drive, seeks Supreme Court intervention over consent, safety and accountability

School-based HPV vaccination may pause; verify consent protocols and legal status before counselling parents or administering doses.

Paediatrics · ETHealthworld · 7 Sept

Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial.

No significant difference in time to first wheezing lower respiratory tract illness: 71 (21%) of 342 with OM-85 versus 61 (18%) of 339 with placebo; hazard ratio 1·16 [95% CI 0·82-1·64], p value 0·35.

Medicine · Lancet · 7 Sept

Artery tertiary lymphoid organs encode a pathogenic high-affinity autoantibody-autoantigen pair in atherosclerosis.

Antibody A6 binds histone H2B with high affinity; vaccination with H2B and adoptive transfer of A6 accelerate atherosclerosis. Anti-H2B titers correlate with aortic calcification in humans.

Medicine · Nature cardiovascular research · 7 Sept

Spatially guided in vivo single-cell functional genomics of postnatal heart.

Identified 21 previously uncharacterized regulators of cardiomyocyte maturation, including genes essential for sarcomere assembly, metabolic reprogramming and electrophysiological transitions.

Medicine · Nature cardiovascular research · 7 Sept

AbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapies

IPO funds will advance siRNA drugs targeting multiple diseases; watch for efficacy data that could expand your therapeutic options.

Medicine · Fierce Biotech · 6 Sept

FSSAI to tighten scrutiny, weighs central ban on non-dairy paneer

A central ban would curb adulterated analogue paneer in your patients' diets, reducing risks from undeclared fats and additives.

General Medicine · ETHealthworld · 6 Sept

Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win

An inhaled pulmonary hypertension therapy showing phase 2 benefit could offer a more targeted option for patients who struggle with systemic side effects from oral vasodilators.

Medicine · Fierce Biotech · 6 Sept

The changing therapeutic landscape of small-cell lung cancer.

No quantitative results reported; describes emerging targeted therapies including T-cell engagers, antibody-drug conjugates, radioconjugates, and cell therapies showing early promise.

Oncology · Lancet · 6 Sept

Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.

Overall survival hazard ratio 1.04 (95% CI 0.69-1.58; p=0.58). 2-year OS 82% in both groups. Grade 3+ adverse events 12% vs 3%.

Oncology · Lancet · 6 Sept

Delhi HC backs NMC: Fragmented foreign medical degrees not enough for FMGE eligibility

If you supervise or train FMGE aspirants, this ruling tightens verification—fragmented foreign training won't qualify, affecting recruitment and credential checks.

General Medicine · ETHealthworld · 5 Sept

Liposuction versus conservative therapy for patients with lipoedema in Germany: a multicentre, randomised controlled clinical trial.

68% (190/278) achieved ≥2-point pain reduction with liposuction vs 8% (10/132) with conservative therapy (OR 26.2, 95% CI 13.1-52.5). Serious adverse events: 8% vs 3%.

General Surgery · Lancet · 5 Sept

Pre-exposure prophylaxis as a complementary vaccination strategy to reduce rabies in Kerala, India: a cost-effectiveness modelling study.

Current practice projected 431 rabies deaths (95% PI 353-523) costing US$50.3 million; PrEP added US$10.5-36.5 million and prevented only ten additional deaths; probability of being optimal ≤12%.

General Medicine · Lancet regional health. Southeast Asia · 5 Sept

Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial

Despite lowering Lp(a), this drug did not cut heart attack or stroke risk—so don't start checking Lp(a) routinely yet.

Cardiology · Fierce Biotech · 5 Sept

FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products

Ensures neonatal intensive care units can keep stocking starter PN for premature infants during potential shortages, preventing treatment delays.

Paediatrics · FDA — Press Announcements · 5 Sept

FDA Grants Accelerated Approval to a New Breast Cancer Treatment

For oncologists in India, this approval signals a new option for advanced breast cancer, but check local availability and cost before changing practice.

Oncology · FDA — Press Announcements · 5 Sept

Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline

First therapy for Alexander disease—an ASO targeting GFAP—offers a disease-modifying option for a fatal leukodystrophy, though availability in India remains unclear.

Neurology · Fierce Biotech · 4 Sept

Menarini signs $771M deal to take Gan & Lee GLP-1 to European market

A new GLP-1 for obesity and diabetes is entering Europe; watch for pricing and supply competition that may affect your patients' access.

Endocrinology · Fierce Biotech · 4 Sept

Medulance Raises ₹24 Cr To Expand Emergency Response Network

Expands ambulance availability and response times for your patients in emergencies, potentially improving critical care access across cities.

General Medicine · Inc42 · 4 Sept

Smoking raises death risk by 55% in people with diabetes, global experts call for active quit treatment

For your diabetic patients who smoke, actively offer cessation—this consensus quantifies a 55% higher death risk and urges routine intervention.

Endocrinology · ETHealthworld · 4 Sept

FSSAI plans curbs on high-fat food sales within 50 metres of schools, CEO Rajit Punhani says

This may reduce childhood obesity and metabolic risk; paediatricians should counsel families on healthier snack choices near schools.

Paediatrics · ETHealthworld · 4 Sept

FDA Approves First Drug to Treat Alexander Disease

First-ever therapy for a fatal leukodystrophy; consider referral for pediatric or adult patients with confirmed GFAP mutation.

Neurology · FDA — Press Announcements · 4 Sept

Ultrahuman Bags $70 Mn To Build An Integrated Healthtech Platform

This funding expands wearable health monitoring, potentially aiding early detection of metabolic and cardiac issues in your patients.

Medicine · Inc42 · 3 Sept

GenHealth.ai secures $16.5M in series A for back-office AI agents

If adopted, these agents could reduce manual revenue-cycle work across EHRs and payer portals, freeing staff time and potentially improving claim throughput.

Medicine · Fierce Healthcare · 3 Sept

STAT+: OpenEvidence launches new family of AI models

If these models improve clinical evidence retrieval, you may get faster, more accurate answers at the point of care—worth trialing in your workflow.

General Medicine · STAT News — Health Tech · 3 Sept

Psilocybin proves promising in neuropathic pain mouse study

If confirmed in humans, psilocybin could offer a new option for chemotherapy-induced neuropathy, which often resists standard painkillers.

Neurology · Fierce Biotech · 3 Sept

AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial

For relapsed/refractory myeloma patients who have exhausted standard options, etentamig offers a new bispecific with improved PFS—consider as a later-line therapy.

Oncology · Fierce Biotech · 3 Sept

STAT+: FDA pilot offers generative AI medical devices a path to patients before they are authorized

FDA's TEMPO pilot may let AI tools like Cadence and Limbic reach your patients pre-authorization—know their evidence limits before you rely on them.

Medicine · STAT News — Health Tech · 3 Sept

OpenEvidence deepens oncology push to enhance specialized AI agent, launches new AI model family

Specialised AI agents may give faster, more accurate oncology answers at the point of care, potentially aiding treatment decisions.

Oncology · Fierce Healthcare · 3 Sept

Scientists find genes linked to OCD, raising the prospect of new treatments

Identifies specific genetic loci for OCD, guiding future targeted therapies and better risk stratification for your patients with refractory symptoms.

Psychiatry · ETHealthworld · 3 Sept

Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study.

Xenograft sustained dialysis independence for 271 days. Early T-cell rejection resolved. Later graft failure from thrombotic microangiopathy despite negative crossmatch. No porcine pathogen transmission. Anti-HLA antibodies unchanged. Human transplant succeeded with 231 days follow-up.

General Surgery · Lancet · 3 Sept

Natural history and clinical impact of epilepsy in adults with Down syndrome: a multicentre clinical study.

Cumulative incidence of epilepsy increased from 9.5% (95% CI 7.8-11.3) at Alzheimer's diagnosis to 56.9% (51.7-61.7) after 9 years. Epilepsy associated with increased mortality (HR 2.10 [95% CI 1.57-2.82]; p<0.0001) and faster cognitive decline.

Neurology · Lancet · 3 Sept

GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset

This deal may bring a novel KRAS-EGFR targeted therapy to your patients with solid tumors, potentially expanding options beyond current KRAS inhibitors.

Oncology · Fierce Biotech · 3 Sept

Pulmonary Nodules.

Solid nodules stable for 2 years considered benign; subsolid nodules require longer stability. Subsolid nodules slower growing but higher malignancy risk, especially if solid component develops.

Radiology · NEJM · 3 Sept

Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology.

Argues first-generation viruses and checkpoint inhibitors rely on pre-existing tumour-specific T cells. Next-generation viruses act as antigen-agnostic in situ vaccines, with early data showing T-cell broadening, abscopal responses, and survival benefit in ICI-refractory disease.

Medicine · Nature reviews. Clinical oncology · 3 Sept

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Median event-free survival 14.5 months (95% CI 10.4-24.4) with azacitidine-venetoclax vs 6.2 months (95% CI 4.1-10.1) with induction; HR 0.57 (95% CI 0.39-0.84, P=0.002).

Oncology · NEJM · 3 Sept

Genetic evidence supports the combined targeting of lipoprotein(a) and LDL cholesterol to reduce coronary artery disease risk.

LPA or PCSK9 loss-of-function carriers had lower CAD risk than noncarriers (odds ratio 0.91 and 0.81); carriers of both had lower risk still (OR 0.73). Genetic lowering of Lp(a) and LDL-C gave OR 0.70 versus OR 0.85 and 0.81 individually.

Medicine · Nature cardiovascular research · 3 Sept

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

Objective response: 31% at ≤120 mg, 34% at 160-220 mg, 37% at 300 mg. Grade 3+ adverse events in 54%; pneumonia 10%, diarrhea 9%, rash 8%, anemia 5%; four grade 5 events.

Oncology · NEJM · 3 Sept

BCL-2 inhibition at antiretroviral therapy initiation reduces the intact SIV reservoir in macaques.

A rapid and sustained reduction of the intact SIV reservoir was seen in venetoclax-treated rhesus macaques in blood and lymph nodes.

Medicine · Nature microbiology · 3 Sept